SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN THE STATEMENTS FILED
PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO
FILED PURSUANT TO RULE 13d-2(b)
(Amendment No. )*
Hollis-Eden Pharmaceuticals, Inc.
---------------------------------
(Name of Issuer)
Common Stock, par value $0.01 per share
--------------------------------------------------------------------------------
(Title of Class of Securities)
435902101
--------------
(CUSIP Number)
June 2, 2005
-------------------------------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[ ] Rule 13d-1(b)
[X] Rule 13d-1(c)
[ ] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
SCHEDULE 13G
CUSIP NO. 435902101 Page 2 of 8
-----------------------------------------------------------------------------
1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)
Cranshire Capital, L.P.
-----------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ]
(b) [ ]
-----------------------------------------------------------------------------
3 SEC USE ONLY
-----------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Illinois
-----------------------------------------------------------------------------
NUMBER OF 5 SOLE VOTING POWER
SHARES 1,333,333 shares of Common Stock (See Item 4)
--------------------------------------------------------------
BENEFICIALLY 6 SHARED VOTING POWER
OWNED BY None
--------------------------------------------------------------
EACH 7 SOLE DISPOSITIVE POWER
REPORTING 1,333,333 shares of Common Stock (See Item 4)
--------------------------------------------------------------
PERSON 8 SHARED DISPOSITIVE POWER
WITH None
-----------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,333,333 shares of Common Stock (See Item 4)
-----------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
[X]
-----------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
6.9% (See Item 4)
-----------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON
PN
-----------------------------------------------------------------------------
SCHEDULE 13G
CUSIP NO. 435902101 Page 3 of 8
-----------------------------------------------------------------------------
1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)
Downsview Capital, Inc.
-----------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ]
(b) [ ]
-----------------------------------------------------------------------------
3 SEC USE ONLY
-----------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Illinois
-----------------------------------------------------------------------------
NUMBER OF 5 SOLE VOTING POWER
SHARES 1,333,333 shares of Common Stock (See Item 4)
--------------------------------------------------------------
BENEFICIALLY 6 SHARED VOTING POWER
OWNED BY None
--------------------------------------------------------------
EACH 7 SOLE DISPOSITIVE POWER
REPORTING 1,333,333 shares of Common Stock (See Item 4)
--------------------------------------------------------------
PERSON 8 SHARED DISPOSITIVE POWER
WITH None
-----------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,333,333 shares of Common Stock (See Item 4)
-----------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
[X]
-----------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
6.9% (See Item 4)
-----------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON
CO
-----------------------------------------------------------------------------
SCHEDULE 13G
CUSIP NO. 435902101 Page 4 of 8
-----------------------------------------------------------------------------
1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)
Mitchell P. Kopin
-----------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ]
(b) [ ]
-----------------------------------------------------------------------------
3 SEC USE ONLY
-----------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
U.S.A.
-----------------------------------------------------------------------------
NUMBER OF 5 SOLE VOTING POWER
SHARES 1,333,333 shares of Common Stock (See Item 4)
--------------------------------------------------------------
BENEFICIALLY 6 SHARED VOTING POWER
OWNED BY None
--------------------------------------------------------------
EACH 7 SOLE DISPOSITIVE POWER
REPORTING 1,333,333 shares of Common Stock (See Item 4)
--------------------------------------------------------------
PERSON 8 SHARED DISPOSITIVE POWER
WITH None
-----------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,333,333 shares of Common Stock (See Item 4)
-----------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
[X]
-----------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
6.9% (See Item 4)
-----------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON
IN
-----------------------------------------------------------------------------
SCHEDULE 13G
CUSIP NO. 435902101 Page 5 of 8
Item 1(a). Name of Issuer:
Hollis-Eden Pharmaceuticals, Inc., a Delaware corporation(the
"Issuer")
Item 1(b). Address of Issuer's Principal Executive Offices:
4435 Eastgate Mall, Suite 400
San Diego, California 92121
Items 2(a), Name of Persons Filing, Address of Principal Business Office and
(b) and Citizenship:
(c).
This Schedule 13G is being filed on behalf of (i) Cranshire
Capital, L.P., an Illinois limited partnership ("Cranshire"),
(ii) Downsview Capital, Inc., an Illinois corporation
("Downsview") and (iii) Mitchell P. Kopin, an individual who is a
citizen of the U.S.A. ("Kopin," together with Cranshire and
Downsview, the "Reporting Persons").
The Reporting Persons have entered into a Joint Filing Agreement,
a copy of which is filed with this Schedule 13G as Exhibit 1,
pursuant to which the Reporting Persons have agreed to file this
Schedule 13G jointly in accordance with the provisions of Rule
13d-1(k) of the Securities Exchange Act of 1934, as amended.
The principal business office of each of the Reporting Persons is
666 Dundee Road, Suite 1901, Northbrook, Illinois, 60062.
Item 2(d). Title of Class of Securities:
Common Stock, par value $0.01 per share, of the Issuer (the
"Common Stock")
Item 2(e). CUSIP Number:
435902101
Item 3. Not applicable.
Item 4. Ownership.
(a) Amount beneficially owned:
1,333,333 shares of Common Stock*
(b) Percent of class:
Based on 19,298,913 shares of Common Stock of the Issuer
outstanding as of June 2, 2005 (as set forth in the Issuer's
Form 424(B)(5) filed on June 2, 2005),
SCHEDULE 13G
CUSIP NO. 435902101 Page 6 of 8
Cranshire holds approximately 6.9% of the issued and
outstanding Common Stock of the Issuer.
(c) Number of shares to which such person has:
(i) Sole power to vote or direct the vote: 1,333,333
shares of Common Stock*
(ii) Shared power to vote or direct the vote: None
(iii) Sole power to dispose or to direct the disposition of:
1,333,333 shares of Common Stock*
(iv) Shared power to dispose of or direct the disposition
of: None
*Cranshire beneficially owns an aggregate of 1,333,333
shares of Common Stock. The beneficial ownership of the
Reporting Persons excludes certain shares of Common Stock
issuable upon the exercise of warrants held by Cranshire.
Such warrants issued to Cranshire contain exercise caps
which prohibit the holder of the warrants from exercising
such warrants to the extent that giving effect to such
exercise, such holder would beneficially own in excess of
4.99% of the Issuer's outstanding Common Stock (determined
in accordance with Section 13(d) of the Securities Exchange
Act of 1934).
Because (i) Downsview is the general partner of Cranshire
and (ii) Kopin is the holder of 100% of the issued and
outstanding shares of Downsview and is the president
thereof, each of Downsview and Kopin are considered to share
the power to vote or direct the vote of, and the power to
dispose or direct the disposition of, the shares of Common
Stock which Cranshire beneficially owns. Each of Downsview
and Kopin disclaim beneficial ownership of the reported
securities except to the extent of each of their respective
pecuniary interests therein, and this statement on Schedule
13G shall not be construed as an admission that each of the
Reporting Persons is the beneficial owner of the Common
Stock covered by such statement.
Item 5. Ownership of Five Percent or Less of a Class.
Not Applicable.
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
Not Applicable.
Item 7. Identification and Classification of the Subsidiary Which
Acquired the Security Being Reported By the Parent Holding
Company.
Not Applicable.
SCHEDULE 13G
CUSIP NO. 435902101 Page 7 of 8
Item 8. Identification and Classification of Members of the Group.
Not Applicable.
Item 9. Notice of Dissolution of a Group.
Not Applicable.
Item 10. Certification.
By signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were not acquired and
are not held for the purpose of or with the effect of changing or
influencing the control of the issuer of the securities and were
not acquired and are not held in connection with or as a
participant in any transaction having that purpose or effect.
SCHEDULE 13G
CUSIP NO. 435902101 Page 8 of 8
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Dated: June 6, 2005
CRANSHIRE CAPITAL, L.P.
By: Downsview Capital, Inc.,
its general partner
By:/s/ Mitchell P. Kopin
------------------------------
Mitchell P. Kopin, President
DOWNSVIEW CAPITAL, INC.
By:/s/ Mitchell P. Kopin
------------------------------
Mitchell P. Kopin, President
/s/ Mitchell P. Kopin
---------------------------------
Mitchell P. Kopin
SCHEDULE 13G
CUSIP NO. 435902101
Exhibit 1
JOINT FILING AGREEMENT
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934,
as amended, the undersigned agree to the joint filing on behalf of each of them
of a statement on Schedule 13G (including amendments thereto) with respect to
1,333,333 shares of Common Stock of Hollis-Eden Pharmaceuticals, Inc., and
further agree that this Joint Filing Agreement shall be included as an exhibit
to such joint filings.
The undersigned further agree that each party hereto is responsible for the
timely filing of such Schedule 13G and any amendments thereto, and for the
completeness and accuracy of the information concerning such party contained
therein; provided, however, that no party is responsible for the completeness or
accuracy of the information concerning any other party making the filing, unless
such party knows or has reason to believe that such information is inaccurate.
IN WITNESS WHEREOF, the parties have executed this Joint Filing Agreement
on June 6, 2005.
CRANSHIRE CAPITAL, L.P.
By: Downsview Capital, Inc.,
its general partner
By:/s/ Mitchell P. Kopin
-------------------------------
Mitchell P. Kopin, President
DOWNSVIEW CAPITAL, INC.
By:/s/ Mitchell P. Kopin
-------------------------------
Mitchell P. Kopin, President
/s/ Mitchell P. Kopin
----------------------------------
Mitchell P. Kopin